(c) Referral of patients to a genetic specialist^a,b.

	PCPsc   n (column %)d   (95%  CI)e	Naturopaths   n (column %)d   (95%  CI)e	OB-GYNs   n (column %)d   (95%  CI)e	Specialistsf   n (column %)d   (95%  CI)e
Referg patients w/o cancer to a genetic specialist for BRCA testing	111 (67.7%)	27 (50.0%)	225 (87.5%)	82 (75.9%)
	(60.1%–74.4%)	(36.9%–63.1%)	(82.9%–91.1%)	(67.0%–83.1%)
Referg patients w/cancer to a genetic specialist for BRCA testing	19 (55.9%)	25 (53.2%)	40 (87.0%)	121 (75.6%)
	(39.1%–71.5%)	(39.0%–66.9%)	(73.8%–94.0%)	(68.3%–81.7%)
Referg patients w/o cancer to a genetic specialist for MMR testing	30 (56.6%)	NAh	105 (91.3%)	122 (77.2%)
	(43.0%–69.2%)		(84.5%–95.3%)	(70.0%–83.1%)
Referg patients w/cancer to a genetic specialist for MMR testing	NAh	NAh	131 (81.9%)	138 (78.0%)
			(75.1%–87.1%)	(71.2%–83.5%)

^aCategory totals may be less than the total number of respondents, due to missing values.

^bBolded estimates indicate significant findings.

^cPCPs: primary care providers which include family physicians, internal medicine physicians, primary care nurse practitioners, and primary care physician assistants.

^dThe column % reflects the percent responding within each practice category.

^eCI: confidence interval.

^fSpecialists consisted of surgeons, colorectal surgeons, general surgeons, gastroenterologists, oncologists, and gynecologic oncologists.

^gAmong providers who suspect a mutation, those who always or usually refer to a genetic specialist.

^hUnable to report estimates due to small cell size.